Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA on Nasdaq, CTRVP on OTC
Location
399 Thornall Street, First Floor, Edison, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 216 % -44.8%
Debt-to-equity 198 % +123%
Return On Equity -1K % -204%
Return On Assets -336 % -92.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.6M shares +100%
Common Stock, Shares, Outstanding 11.6M shares +100%
Entity Public Float 5.9M USD -85.4%
Common Stock, Value, Issued 1.16K USD +112%
Weighted Average Number of Shares Outstanding, Basic 11.3M shares +9667%
Weighted Average Number of Shares Outstanding, Diluted 11.3M shares +9667%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 2.62M USD -88.9%
General and Administrative Expense 5.67M USD -28.6%
Operating Income (Loss) -8.69M USD +75%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -13.6M USD +57.3%
Income Tax Expense (Benefit) -3.38M USD -17.1%
Net Income (Loss) Attributable to Parent -13.6M USD +52.2%
Earnings Per Share, Basic -47 USD/shares +92.9%
Earnings Per Share, Diluted -47 USD/shares +92.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 4.51M USD -17.8%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 66.5K USD
Assets 4.51M USD -25%
Accounts Payable, Current 173K USD -61.3%
Employee-related Liabilities, Current 0 USD -100%
Accrued Liabilities, Current 48.5K USD -87.1%
Liabilities, Current 593K USD -39.2%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 41.2K USD
Liabilities 709K USD -71.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8.35K USD
Retained Earnings (Accumulated Deficit) -245M USD -5.86%
Stockholders' Equity Attributable to Parent 3.8M USD +6.6%
Liabilities and Equity 4.51M USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.12M USD +69.1%
Net Cash Provided by (Used in) Financing Activities 5.3M USD +186%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 11.6M shares +100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.18M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.92M USD +38.3%
Deferred Tax Assets, Valuation Allowance 44.6M USD +0.09%
Deferred Tax Assets, Gross 44.6M USD -0.05%
Operating Lease, Liability 0 USD -100%
Depreciation 100K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.5M USD +52.4%
Lessee, Operating Lease, Liability, to be Paid 139K USD -46.9%
Operating Lease, Liability, Current 118K USD +5.05%
Lessee, Operating Lease, Liability, to be Paid, Year Two 97.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 97.8K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +123%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.3K USD +2.97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Additional Paid in Capital 234M USD +1.72%
Current State and Local Tax Expense (Benefit) -3M USD
Depreciation, Depletion and Amortization 30.8K USD +70.5%
Deferred Tax Assets, Net of Valuation Allowance 62.5K USD -88.9%
Share-based Payment Arrangement, Expense 107K USD -91.1%
Interest Expense 11.5K USD +11.8%